No registrations found.
ID
Source
Brief title
Health condition
Gastric cancer
Neoadjuvant chemotherapy
Maagkanker
Neoadjuvante chemoradiatie
Sponsors and support
Intervention
Outcome measures
Primary outcome
The primary endpoint is the possible delay in performing a curative resection due to increased toxicity of more than 10% with a stopping point at a delay in six patients.
Secondary outcome
Secondary endpoints are occurrence of downstaging and changes in pathology (pathological responses).
Tissue and serum before and after treatment for genomic profiling, kinome profiling (kinase activity) and protein expression will be collected to determine patterns to predict response to therapy.
1. To determine pathological responses;
2. To determine genomic profile to predict response to treatment;
3. To determine the number of R0 resections;
4. To determine progression free survival;
5. To detect risk of tumor recurrence patterns.
Furthermore we will assess quality of life (QOL) before, during and after this combined treatment.
Background summary
Rationale:
The incidence of gastric cancer has been declining steadily since the 1930s, but it remains a major cause of cancer death in the Western world. The high mortality rate reflects the prevalence of advanced disease at presentation. The five-year survival rate for patients with completely resected early stage gastric cancer is approximately 75%, while it is 30% or less for patients who have extensive lymph node involvement. However, nearly 70-80% of the resected gastric carcinoma specimens have regional lymph nodes and over 80% of patients who die from gastric cancer experience a local recurrence at some time in their disease. These sobering results have gathered efforts to improve treatment results for these patients using adjuvant (postoperative) or neoadjuvant (preoperative) radiation therapy (RT) and/or chemotherapy. The rational for chemoradiation is the risk for locoregional recurrence and distant metastases. Radiation with surgery can improve locoregional control while systematic chemotherapy can eliminate microscopic distant metastases. As limited data that exist, fail to show a survival benefit from the addition of postoperative RT alone in patients with resected gastric cancer, almost all postoperative RT trials have included concurrent chemotherapy to improve the efficacy of RT ("radiation sensitization"). Over time adjuvant chemoradiation is considered as standard of care after curative surgery for adenocarcinoma of stomach cancer in many countries. Preoperative chemoradiotherapy in locally advanced gastric cancer results in significant down staging of the tumor with improved rate of curative resections.
Chemotherapy may also function as a radiosensitiser, improving the effect of radiation by double-stranded DNA breaks and inhibition of DNA repair by blocking the cell cycle at the G2/M phase. Recent studies have shown activity of Paclitaxel in conjunction with radiation in gastric cancer.
Purpose: To evaluate the feasibility and safety of a combination of preoperative chemoradiation of Paclitaxel 50mg/m2 and Carboplatin AUC 2 given intravenously on day 1, 8,15, 22 and 29 in combination with 45 Gy (fractions of 1.8Gy) for locally advanced adenocarcinoma of the stomach.
Type:
Interventional
Design:
Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, feasibility study
The sample size for this study will be 14 patients in order to determine as <10% delay, defined as surgery after 5 weeks after last course of chemotherapy. The delay of 10% is conform other studies concerning neo-adjuvant treatment. If a delay occurs in more than 5 patients the study will be stopped.
Endpoints:
Primary endpoint: will be feasibility, defined as less than 10% toxicity leading to postponement of surgery.
Secondary endpoints: occurrence of down staging and changes in pathology.
Study objective
The incidence of gastric cancer has been declining steadily since the 1930s, but it remains a major cause of cancer death in the Western world. The high mortality rate reflects the prevalence of advanced disease at presentation. The five-year survival rate for patients with completely resected early stage gastric cancer is approximately 75%, while it is 30% or less for patients who have extensive lymph node involvement. However, nearly 70-80% of the resected gastric carcinoma specimens have regional lymph nodes and over 80% of patients who die from gastric cancer experience a local recurrence at some time in their disease. These sobering results have gathered efforts to improve treatment results for these patients using adjuvant (postoperative) or neoadjuvant (preoperative) radiation therapy (RT) and/or chemotherapy. The rational for chemoradiation is the risk for locoregional recurrence and distant metastases. Radiation with surgery can improve locoregional control while systematic chemotherapy can eliminate microscopic distant metastases. As limited data that exist, fail to show a survival benefit from the addition of postoperative RT alone in patients with resected gastric cancer, almost all postoperative RT trials have included concurrent chemotherapy to improve the efficacy of RT ("radiation sensitization"). Over time adjuvant chemoradiation is considered as standard of care after curative surgery for adenocarcinoma of stomach cancer in many countries. Preoperative chemoradiotherapy in locally advanced gastric cancer results in significant down staging of the tumor with improved rate of curative resections.
Chemotherapy may also function as a radiosensitiser, improving the effect of radiation by double-stranded DNA breaks and inhibition of DNA repair by blocking the cell cycle at the G2/M phase. Recent studies have shown activity of Paclitaxel in conjunction with radiation in gastric cancer.
Study design
Surgery will be performed preferably within 4 - 6 weeks after the completion of the chemoradiation.
After completion of the protocol, patients will be followed up every 3 months for the first year, every 6 months for the second year, and then at the end of each year until 5 years after treatment, to document late toxic effects and, if applicable, disease relapse or progression, and death.
Intervention
Intervention is the use of chemoradiotherapy as an adjunct to the standard surgical resection. As adjuvant chemoradiation has soms disadvantages such as an improved possibility to abandon chemoradiotherapy because of postoperative complications leading to a too long postoperative course. Therefore neoadjuvant application has several advantages such as good performane status, better response measuring and more curative resections.
University Medical Center Groningen
PO Box 30.001
G.A.P. Hospers
Groningen 9700 RB
The Netherlands
+31 (0)50 3616161
g.a.p.hospers@int.umcg.nl
University Medical Center Groningen
PO Box 30.001
G.A.P. Hospers
Groningen 9700 RB
The Netherlands
+31 (0)50 3616161
g.a.p.hospers@int.umcg.nl
Inclusion criteria
1. Histologically proven and documented adenocarcinoma of the stomach;
2. Surgical resectable gastric cancer stage IB-IVA: T1N1; T2-4, N0-1, M0 (see appendix), as determined by Endoscopic Ultra Sound (EUS), Computed Tomography (CT);
3. Age ¡Ý18 and ¡Ü75;
4. Ambulatory performance status (WHO scale 0-2(see appendix);
5. No prior chemotherapy;
6. No prior radiotherapy;
7. If more than 50% of the tumor extends above the gastroesophageal (GE) junction into the esophagus, the bulk of the tumor must involve the stomach. The tumor must not extend more than 2 cm into esophagus;
8. Adequate hematological, renal and hepatic functions defined as:
a. White blood cell count ¡Ý4.0 x 109/L;
b. Platelet count ¡Ý100 x 109/L;
c. Serum bilirubin ¡Ü 1.5 x upper normal limit;
d. Calculated Creatinine Clearance ¡Ý50 ml/min (cockcroft formula);
e. Two equally functioning kidneys determined with standard technology(renogram);
9. Tumor negative laparoscopy when CT suggests peritoneal carcinomatosis;
10. Written, voluntary informed consent (interval between information and consent at least 7 days);
11. Patients must be accessible to follow up and management in the treatment center;
12. Patients must sufficiently understand the Dutch language and must be able to sign the informed consent document.
Exclusion criteria
1. T1N0 tumors and in situ carcinoma (endoscopic ultrasound) are not eligible;
2. Distant metastases;
3. In case of only one functional kidney;
4. Previous or current malignancies at other sites than entry diagnosis except for adequately treated basal or squamous cell carcinoma of the skin, or curatively treated carcinoma in situ of the cervix uteri;
5. Prior chest or upper abdomen radiotherapy, prior systemic chemotherapy, or prior esophageal or gastric surgery;
6. Evidence of serious active infections;
7. Severe cardiac and/or pulmonary failure, uncontrolled hypertension, angina pectoris;
8. Clinical signs of myocardial ischaemia;
9. Dementia or altered mental status that would prohibit the understanding and giving of informed consent;
10. Pregnant or lactating women. Sexually active patients of childbearing potential must implement effective contraceptive practices during the study when treated with chemotherapy.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1564 |
| NTR-old | NTR1644 |
| Other | NL : 18509.042.07 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |
Summary results
2. van der Sanden GA, Coebergh JW, Schouten LJ, Visser O, van Leeuwen FE. Cancer incidence in The Netherlands in 1989 and 1990: first results of the nationwide Netherlands cancer registry. Coordinating Committee for Regional Cancer Registries. Eur J Cancer 1995;31A(11):1822-9.<br>
3. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83(1):18-29.<br>
4. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37 Suppl 8:S4-66.<br>
5. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982:8:1-11<br>
6. Landry J, Tepper JE, Wood WC etal: Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990:19:1357-62<br>
7. Xiong HQ, Gunderson LL, Yao J, Ajani JA. Chemoradiation for resectable gastric cancer. Review. Lancet Oncology 2003;4:498-505.<br>
8. Akoh JA, Macintyre IMC: Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg 79:293-299, 1992<br>
9. Kinoshita T, Maruyama K, Sasako M, et al: Treatment results of gastric cancer patients: Japanese experience. Tokyo, Berlin, Heidelberg, Springer-Verlag, 1993<br>
10. Maruyama K, Gunven P, Okabayashi K, et al: Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg 210:596-602, 1989<br>
11. Maruyama K, Gunven P, Okabayashi K, et al: Lymph node metastases of gastric cancer. General pattern in 1931 patients. Ann Surg 210:596-602, 1989<br>
12. Cuschieri A: Recent advances in gastrointestinal malignancy. Ann Chir Gynaecol 78:228-237, 1989<br>
13. Bonenkamp JJ, van de Velde CJH, Kampschöer GHM, et al: Comparison of factors influencing the prognosis of Japanese, German, and Dutch Gastric cancer patients. World J Surg 17:410-415, 1993<br>
14. Katai H, Maruyama K, Sasako M, et al: Mode of recurrence after gastric cancer surgery. Dig Surg 11:99-103, 1994<br>
15. Sue-Ling HM, Johnston D, Martin IG, et al: Gastric cancer: a curable disease in Britain. BMJ 307:591-596, 1993<br>
16. Hartgrink HH, van der Velde CJ, Putten H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-77<br>
17. Nashimoto A, Nakajima T, Furukawa H, et al: Randomised trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan clinical oncology group 9206-1. J Clin Oncol 21:2282-2287, 2003<br>
18. Siewert JR, Böttcher K, Roder JD, et al: Prognostic relevance of systhemic lymph node dissection in gastric carcinoma. Br J Surg 80:1015-1018, 1993 <br>
19. Wanebo HJ, Kennedy BJ, Winchester DP, et al: Gastric carcinoma: does lymph node dissection alter survival? J Am Coll Surg 183:616-624, 1996<br>
20. Dent DM, Madden MV, Price SK: Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 75:110-112, 1988<br>
21. Robertson CS, Chung SCS, Woods SDS, et al: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 220:176-182, 1994<br>
22. Bonenkamp JJ, Sasako M, Hermans J, et al: Extended lymph-node dissection for gastric cancer. N Engl J Med 340:908-914, 1999<br>
23. Cuschieri A, Weeden S, Fielding J, et al: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 79:1522-1530, 1999<br>
24. Hundley JC, Shen P, Shiver SA, et al: Lymphatic mapping for gastric adenocarcinoma. Am Surg 68:931-5, 2002<br>
25. Birkmeyer JD, Stukel TA, Siewers AE, et al: Surgeon volume and operative mortality in the United States. N Engl J Med 249:2117-27, 2003<br>
26. MacDonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730, 2001<br>
27. Hallissey MT, Dunn JA, Ward LC et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 343:1309-1312;1994<br>
28. Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, Eyre HJ, Solanki D, Cruz AB Jr, Gagliano R. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 1995; 2: 488-494 <br>
29. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35: 1059-1064 <br>
30. Allum W, Cunningham D, Weeden S, et al: Peri-operative chemotherapy in operable gastric and lower oesophageal cancer: randomised controlled trial (the MAGIC Trial). Proc Am Soc Clin Oncol 22:A998, 2003<br>
31. Cunnigham D, Allum WH, Stenning SP et al. Perioperative chemotherapy in operable gastric cancer and lower oesophageal cancer: final results of a randomised controlled trial (MAGIC trial, ISRCTN 93793971) Proc. Am Soc Clin Oncol 2005<br>
32. Park SH, Kim DY, Heo JS, et al: Postoperative chemoradiotherapy for gastric cancer. Ann Oncol 14:1373-7, 2003<br>
33 Hazard L. O'Connell J and Scaife C. Role of radiotherapy in gastric adenocarcinoma W.J.Gastroenterology 2006;12:1511-1520<br>
33. Smalley SR, Gunderson L, Tepper J et al Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int Radiat Oncol Biol Phys 2002: 52:283-293<br>
34. Hartgrink HH, van de Velde CJH, Putter H, et al: Neo-adjuvant chemotherapy for operable gastric cancer; long-term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 30:643-9, 2004<br>
35. Roth AD, et al Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I¨CII study Ann of Oncol 2003:14;110-115 <br>
36. Frei E, Miller D, Clark JR et al. Clinical and scientific considerations on preoperative (neoadjuvant) chemotherapy. Rec Res Cancer Res 1986;103:1-5<br>
37. Ajani JA, Ota DM, Jessup JM et al. Resectable gastric cancer an evaluation of preoperative and postoperative chemotherapy. Cancer 1991;68:1501-6.<br>
38. Ajani JA, Mayer RJ, Ota DM et al. Preoperative and postoperative chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993;85:1839-44<br>
39. Ajani JA, Mansfield PF, Ota DM Potentially resectable gastric carcinoma; current approaches to staging and preoperative therapy. World J Surg 1995;19:216-20<br>
40. Lowy AM, Mansfield PF, Leach SD et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer Ann Surg 1999;229:303-8.<br>
41. Safran H, King T, Choy H et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J Clin oncol 1997;15:901-7<br>
42. Safran H, Wanebo HJ, Hesketh PJ et al. Paclitaxel and concurrent radiation for gastric cancer. Int J Radiation Oncol Bio Phys 2000:46:889-94 <br>
43. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD. Investigation of taxol as a potential radiation sensitizer. Cancer 1993;71(11):3774-8.<br>
44. Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992;22(3):613-7.<br>
45. Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 1996;56(22):5198-204.<br>
46. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13(1):180-90.<br>
47. Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998;16(10):3316-22.<br>
48. Choy H, Devore RF, 3rd, Hande KR, et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 2000;47(4):931-7.<br>
49. Lau D, Leigh B, Gandara D, et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 2001;19(2):442-7.<br>
50. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13(1):180-90.<br>
51. Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998;16(10):3316-22.<br>
52. Choy H, Devore RF, 3rd, Hande KR, et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 2000;47(4):931-7.<br>
53. Lau D, Leigh B, Gandara D, et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 2001;19(2):442-7.<br>
54. Tsai JY, Iannitti D, Berkenblit A, et al. Phase I study of docetaxel, capecitabine, and carbolatin in metastatic esophagogastric cancer. Am J Clin Oncol 2005;28:329-33.<br>
55. Huang S and Harari PM. Modulation of Radiation receptor blockade in sqaumous cell carcinoma; inhibition of damage repair cell cycle kinetics and tumorangiogenesis Clin Cancer Research 2000;6:2166<br>
56. Bonner JA,Harari PM, Giralt J et al: Radiotherapy plus Cetuximab for squamous cell carcinoma of the Head and Neck. N Engl J Med 2006;354:567-578